James R. Rodrigue, Douglas W. Hanto, Michael P. Curry – 1 October 2013 – Many liver transplantation (LT) programs require substance abuse (SA) treatment for candidates with a history of alcohol abuse. However, there are no data indicating that SA treatment prevents post‐LT alcohol relapse. We examined 118 adults who underwent LT from May 2002 to February 2011 to explore the relationship between SA treatment and post‐LT relapse to any alcohol use. Sixty‐one patients (52%) with a history of alcohol abuse or dependence received SA treatment before LT.

Markus Peck‐Radosavljevic, Wolfgang Sieghart, Florian Hucke, for the Vienna HCC Study Group – 1 October 2013

Ju Dong Yang, Manal F. Abdelmalek, Herbert Pang, Cynthia D. Guy, Alastair D. Smith, Anna Mae Diehl, Ayako Suzuki – 1 October 2013 – Estrogens inhibit stellate cell activation and fibrogenesis. Thus, gender and reproductive states may influence the degree of fibrosis in patients with nonalcoholic steatohepatitis (NASH).

Donald B. Smith, Jens Bukh, Carla Kuiken, A. Scott Muerhoff, Charles M. Rice, Jack T. Stapleton, Peter Simmonds – 1 October 2013 – The 2005 consensus proposal for the classification of hepatitis C virus (HCV) presented an agreed and uniform nomenclature for HCV variants and the criteria for their assignment into genotypes and subtypes. Since its publication, the available dataset of HCV sequences has vastly expanded through advancement in nucleotide sequencing technologies and an increasing focus on the role of HCV genetic variation in disease and treatment outcomes.

1 October 2013

Alberto Sanchez‐Fueyo – 23 September 2013

Adalbert Krawczyk, Hedwig Roggendorf, Charlotte Ludwig, Kerstin Herzer, Guido Gerken, Peter A. Horn, Michael Roggendorf, Monika Lindemann – 23 September 2013

Sanjiv Saigal, Narendra S. Choudhary, Neeraj Saraf, Sushila Kataria, Ravi Mohanka, Arvinder S. Soin – 23 September 2013

Michel Blé, Victoria Aguilera, Angel Rubín, María García‐Eliz, Carmen Vinaixa, Martín Prieto, Marina Berenguer – 23 September 2013 – Hepatitis C virus (HCV) is associated with renal complications. We aimed to determine whether a sustained virological response (SVR) was associated with improvements in renal function (RF) in liver transplant (LT) recipients treated for HCV. Changes in RF were compared 1, 3, and 5 years after therapy as a function of the stage of chronic kidney disease (CKD) before treatment (BT).

Henry C. Lin, Luis Alvarez, Greggy Laroche, Hector Melin‐Aldana, Kim Pfeifer, Kathleen Schwarz, Peter F. Whitington, Estella M. Alonso, Udeme D. Ekong – 23 September 2013 – Progressive familial intrahepatic cholestasis type 2 (PFIC2) results from recessive mutations in the adenosine triphosphate–binding cassette B11 gene, which encodes for bile salt export pump (BSEP). Liver transplantation (LT) is offered to PFIC2 patients with end‐stage liver disease.